ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,767.50
0.10%
S&P ASX All Technology
3,137.90
0.55%
Brent Oil
84.85
0.00%
US Dollar vs AUD
1.49566
0.00%
Bitcoin
60,740.00
-0.25%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. NanoViricides Inc (NNVC)

  7. NanoViricides Inc (NNVC) News

NNVC

NanoViricides (NNVC)

NanoViricides Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:NNVC
DateTimeSourceHeadlineSymbolCompany
03/05/202400:07InvestorsHub NewsWireNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonAMEX:NNVCNanoViricides Inc
17/02/202408:53Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
15/02/202408:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NNVCNanoViricides Inc
20/01/202408:44Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
05/12/202308:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NNVCNanoViricides Inc
14/10/202307:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:NNVCNanoViricides Inc
29/09/202306:44Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:NNVCNanoViricides Inc
02/09/202306:46Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
07/07/202301:16InvestorsHub NewsWireClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical NeedsAMEX:NNVCNanoViricides Inc
26/05/202306:34Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
09/05/202307:20Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:NNVCNanoViricides Inc
04/05/202320:45GlobeNewswire Inc.NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityAMEX:NNVCNanoViricides Inc
15/02/202309:24Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
14/02/202309:02Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
23/12/202222:04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:NNVCNanoViricides Inc
16/11/202208:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
05/11/202207:33Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:NNVCNanoViricides Inc
14/10/202208:13Edgar (US Regulatory)Annual Report (10-k)AMEX:NNVCNanoViricides Inc
30/09/202202:20Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
11/08/202208:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NNVCNanoViricides Inc
17/05/202206:55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
16/11/202108:55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
15/11/202123:09InvestorsHub NewsWireNanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2AMEX:NNVCNanoViricides Inc
12/10/202121:16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
11/10/202121:49InvestorsHub NewsWireNanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus ActivityAMEX:NNVCNanoViricides Inc
05/10/202121:45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
05/10/202121:45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
29/09/202106:32Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
22/09/202120:48InvestorsHub NewsWireSignificantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
22/09/202120:45PR Newswire (US)Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
 Showing the most relevant articles for your search:AMEX:NNVC

Your Recent History

BIT
P1UV76
NLBNPIT1UV76 20351221 5....
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved